MedPath

Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism

Completed
Conditions
Idiopathic Hypogonadotropic Hypogonadism
Interventions
Drug: Sustanon 250 mg ampule (Testosterone esters)
Registration Number
NCT01758094
Lead Sponsor
Gulhane School of Medicine
Brief Summary

The aim of the present study was to demonstrate the RBP4 levels, association of RBP4 with insulin resistance and influence of testosterone treatment on this cytokine in patients with idiopathic hypogonadotropic hypogonadism.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
25
Inclusion Criteria

decreased serum testosterone concentration below the normal range (serum T < 300ng/dL), FSH and LH levels within or below the normal range, absence of a pituitary or hypothalamic mass lesions on MRI, presence of gonadotropin response to repetitive doses of GnRH, normal smell test and normal karyotypes

Exclusion Criteria

previous androgen treatment, history of smoking, presence of bilateral anorchia, intellectual deficiency, diabetes mellitus, arterial hypertension or dyslipoproteinemia, medication of any kind and drug abuse. Because of possible confounding effects, patients with other hormone deficiencies were excluded.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Hypogonadotropic hypogonadism patientsSustanon 250 mg ampule (Testosterone esters)Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
Primary Outcome Measures
NameTimeMethod
Retinol binding protein 4, hs-CRP levels in patients with idiopathic hypogonadotrophic hypogonadism2008-2012
Secondary Outcome Measures
NameTimeMethod
Effect of testosterone treatment on retinol binding globulin 4 and hs-CRP levels in patients with hypogodotrophic hypogonadism2008-2012

Trial Locations

Locations (1)

Gulhane School of Medicine Dep. of Endocrinology and Metabolism

🇹🇷

Ankara, Turkey

© Copyright 2025. All Rights Reserved by MedPath